INVO Fertility Inc (IVF) FinancialsIVFFinancialINVO Fertility Inc

INVO Fertility Inc (IVF) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinic revenue, accounting for 99.6% of total sales, equivalent to $2.17M. Another important revenue stream is Domestic product revenue. Understanding this composition is critical for investors evaluating how IVF navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, INVO Fertility Inc maintains a gross margin of 28.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.28%, while the net margin is 40.85%. These profitability ratios, combined with a Return on Equity (ROE) of -203.65%, provide a clear picture of how effectively IVF converts its operational activities into shareholder value.

In the context of the broader market, IVF competes directly with industry leaders such as NIVF and EDVA. With a market capitalization of $2.66M, it holds a significant position in the sector. When comparing efficiency, IVF's gross margin of 28.37% stands against NIVF's 36.79% and EDVA's 43.75%. Such benchmarking helps identify whether INVO Fertility Inc is trading at a premium or discount relative to its financial performance.

INVO Fertility has shown a strong revenue growth trajectory, with Q2 2026 revenue increasing by 17% compared to Q2 2025. The company has also improved its cash position, increasing reserves to $3.7 million, and reduced its operating loss significantly from $3 million to $1.3 million in the same quarter.